home / stock / abvc / abvc news

ABVC News and Press, ABVC BioPharma Inc. From 06/26/23

Stock Information
Company Name: ABVC BioPharma Inc.
Stock Symbol: ABVC
Market: NASDAQ
Website: abvcpharma.com
Menu
ABVC ABVC Quote ABVC Short ABVC News ABVC Articles ABVC Message Board
Get ABVC Alerts

News, Short Squeeze, Breakout and More Instantly...
ABVC - ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

FREMONT, CA - ( NewMediaWire ) - June 26, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam)   a...
ABVC - ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced today that its wholly owned subsidiary, BioKey...

ABVC - ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

FREMONT, CA - ( NewMediaWire ) - June 12, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neuropsychiatric conditions, and ophthalmology, today announced that the first subjec...

ABVC - ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

FREMONT, CA, June 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today a...
ABVC - ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS) disorders, and ophthalmology, today announced that the Vi...

ABVC - ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder

FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it received a US patent certificate, US 11,554...

ABVC - ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF

Fremont, CA - ( NewMediaWire ) - April 26, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the site initiation visits (SIV) at the University of California ...
ABVC - ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

Fremont, CA - ( NewMediaWire ) - April 10, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Phase 1 Site Initiation Visit (SIV) of ABV-1601 was s...

ABVC - ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

Fremont, CA - ( NewMediaWire ) - April 06, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus® Phase II Site Initiation Visit (SIV) at Ramathibod...

ABVC - ABVC BioPharma GAAP EPS of -$0.52, revenue of $0.97M

2023-04-03 01:34:38 ET ABVC BioPharma press release ( NASDAQ: ABVC ): FY GAAP EPS of -$0.52. Revenue of $0.97M (+169.4% Y/Y). For further details see: ABVC BioPharma GAAP EPS of -$0.52, revenue of $0.97M
Previous 10 Next 10